Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
16 avr. 2024 16h05 HE
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., April 16, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH),...
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis
09 avr. 2024 08h00 HE
|
Madrigal Pharmaceuticals, Inc.
Rezdiffra is the first and only medication approved by the FDA for the treatment of NASH (also known as “MASH”) First patients have received Rezdiffra via Madrigal’s specialty pharmacy network ...
Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
26 mars 2024 06h00 HE
|
Gyre Therapeutics, Inc.
Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum
21 mars 2024 07h00 HE
|
Gyre Therapeutics, Inc.
Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum
Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering
18 mars 2024 23h58 HE
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., March 18, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic...
Madrigal Pharmaceuticals Announces Proposed Public Offering
18 mars 2024 16h04 HE
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., March 18, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic...
FDA’s Approval of Breakthrough NASH Treatment Opens Door for a Long-Neglected Patient Population
14 mars 2024 17h18 HE
|
Global Liver Institute
Washington, DC, March 14, 2024 (GLOBE NEWSWIRE) -- Today, Global Liver Institute (GLI) recognizes the importance of the first approval by the U.S. Food and Drug Administration (FDA) of a medication...
Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis
14 mars 2024 16h15 HE
|
Madrigal Pharmaceuticals, Inc.
Rezdiffra becomes the first and only medication approved by the FDA for the treatment of NASH (also known as “MASH”)Accelerated approval was based on Phase 3 data demonstrating that Rezdiffra improved...
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
06 mars 2024 16h05 HE
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., March 06, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...
Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis
05 mars 2024 08h00 HE
|
Madrigal Pharmaceuticals, Inc.
MAA submission is supported by positive results from MAESTRO-NASH, the only Phase 3 trial in NASH to achieve fibrosis reduction and NASH resolution primary endpointsResmetirom new drug application is...